june 13, 2017

Recensa is one of Three Phase 1 Ventures Participants to Receive Science Center Funding

Three newly formed companies have received $50,000 each from the University City Science Center’s Phase 1 Ventures (P1V) program. PolyCeramX, Recensa Therapeutics and Regennera, all P1V participants, will apply the funds to a combination of technical development and commercialization activities.

Phase 1 Ventures is a startup accelerator that helps launch and grow companies that have specific technology and/or regulatory development needs, such as healthcare, materials, or energy. P1V participants include entrepreneurs that are matched to a technology at one of P1V’s participating universities or recently formed companies that have not yet raised financing. Since it was launched in 2015, P1V has committed more than $1.6 million to 19 startups, typically as the first investment. Collectively, these participants have raised close to $2 million in non-dilutive funding and $1 million in follow-on investment to date.

With intellectual property from Temple University, PolyCeramX is developing a new solid state electrolyte to increase the safety, efficacy and device incorporation of lithium batteries. These solid state electrolytes reduce flammability due to their composition. Because they are flexible and conforming, they can be fabricated into various sized and shaped devices and have higher conductivities than current competitors.

Recensa Therapeutics, also with IP from Temple, possesses a technology which screens for molecules that stimulate the body’s anti-oxidant response against inflammation. Recensa is using this technology to develop topical therapies for the treatment of psoriasis.

Regennera is developing a novel pre-vascularized, load-bearing synthetic bone graft with IP from Rutgers, The State University of New Jersey. This all-in-one fracture repair device is capable of developing new bone and vasculature simultaneously by combining a composite polymeric/hydroxyapatite structural element that mimics both trabeculae and cortical bone (which are both critical for proper bone regrowth) and cells from the patient's bone marrow.

Launched in 2015, P1V’s portfolio currently includes 19 newly formed companies leveraging intellectual property from 12 institutions, including The Children’s Hospital of Philadelphia; Drexel University; Lehigh University; Penn State University; Rutgers, The State University of New Jersey; Temple University; Thomas Jefferson University; University of Delaware; University of Iowa; University of Pennsylvania; University of Pittsburgh; and University of the Sciences.

About the Science Center
Located in the heart of uCity Square, the Science Center is a mission-driven nonprofit organization that catalyzes and connects innovation to entrepreneurship and technology commercialization. For 50+ years, the Science Center has supported startups, research, and economic development in the life sciences, healthcare, physical sciences, and emerging technology sectors. As a result, graduate firms and current residents of the Science Center’s incubator support one out of every 100 jobs in the Greater Philadelphia region and drive $13 billion in economic activity in the region annually. By providing resources and programming for any stage of a business’s lifecycle, the Science Center helps scientists, entrepreneurs and innovators take their concepts from idea to IPO – and beyond.

For more information about the Science Center, go to http://www.sciencecenter.org


may 25, 2017

Recensa named Best in show & most fundable at 1st pitch life sciences

NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Mid Atlantic Bio Angels (MABA) announces today that Recensa Therapeutics, which is developing a topical psoriasis treatment designed to reduce oxidative stress, was named “Best in Show” by the audience and “Most Fundable” by the investor panel at MABA's 1st Pitch Life Science event held on May 25, 2017 at Rockefeller University in New York City.

“We are honored to be chosen as winner of both ‘Best in Show’ and ‘Most Fundable,’” said Matt Handel, President of Recensa Therapeutics. “Recensa’s co-founder, Dr. Oscar Perez, and I are dedicated to improving the lives of patients with psoriasis by developing the first topical pharmaceutical to target oxidative stress in this disease. We are gratified that the panel validated our approach. We will now use the excellent questions and comments from the audience and the insightful feedback from the experts to improve our communications and development plan.”

Philadelphia-based Recensa Therapeutics is developing proprietary, first-in-class small molecules that activate the transcription factor Nrf2, a key mediator of the oxidative response.  Rather than modulating the immune system, Recensa’s Nrf2 activators leverage the body’s own antioxidants to stop the inflammatory cycle. The company’s current investigational molecules are designed to target mild-to-moderate psoriasis, with the possibility of becoming adjunct therapy for moderate-to-severe psoriasis in combination with systemic treatments.

“Recensa offered a well-structured pitch, describing a clear medical need, the limitations of existing treatments and the distinct advantages of their product,” said Stephen M. Goodman, co-founder of MABA and a partner at the law firm of Pryor Cashman LLP.  “I would expect that with some refinement of the pitch, the company will likely garner investor interest.”

About 1st Pitch Life Science
At a 1st Pitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1stPitch are invited to hear the panel constructively critique the company's presentation, business model and perceived viability in the market.

About MABA
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.


April 19, 2017

RECENSA THERAPEUTICS NAMED A BEST UNIVERSITY STARTUP OF 2017

Recensa Therapeutics, Inc. was selected as one of the 40 "Best University Startups 2017" by the National Council of Entrepreneurial Tech Transfer. As part of this award, Recensa presented at the University Startups Conference and Demo Day on April 19, 2017 in Washington, D.C.

Best University Startup.png